OrthogenRx markets GenVisc 850 and TriVisc biologic products. OrthogenRx executes at a level of efficiency that allows them to invest in pricing programs.
The company has completed recruitment and treated all patients in its Phase III study with the viscosupplement, JTA-004, in patients with knee osteoarthritis.